NCT02490904View on ClinicalTrials.gov

Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

October 19, 2016

Primary Completion Date

November 9, 2021

Study Completion Date

August 31, 2031

Conditions
End-stage Renal Disease
Interventions
DRUG

Eplerenone

Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours

DRUG

Placebo

Double-blinded Placebo administered for 4 days at 25mg every 12 hours

Trial Locations (7)

Unknown

CHRU Besançon, Besançon

CHU Brest, Brest

CHU Dijon- Hôpital Bocage Central, Dijon

CHRU de Nancy, Nancy

CHU Reims-Hôpital Maison Blanche, Reims

CHU Saint Etienne, Saint-Etienne

NHC -CHRU Strasbourg, Strasbourg

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER